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Abstract
Multiple endocrine neoplasia type 1 (MEN1) is an 
autosomal dominant inherited tumour syndrome 
expressing various endocrine and non-endocrine lesions 
and tumours. Since the identification of the causative 
gene, the oncosuppressor gene MEN1, in 1997, genetic 
testing has revealed an important approach for the 
early and differential diagnosis of the disease. The 
finding of a MEN1 mutation in a patient has important 
clinical implications for relatives since it allows very 
early disease diagnosis and identification of carriers, 
even before biochemical and/or clinical manifestation, 
permitting their inclusion in a specific program of 
surveillance and subsequent praecox therapy. Currently, 
genetic testing for MEN1 consists principally of the 
sequencing of coding regions and intron-exon junctions 
of the MEN1 gene. However, the recent acquisition of 
novel high throughput technologies will allow the design 
of innovative, accurate, complete and rapid genetic 
diagnosis. These new tools are able to increase the 
strength of the analysis and almost completely eliminate 
the possibility of false negative results. This review 
aims to give an overview on genetic testing of MEN1 
syndrome, reporting the positive aspects of performing 
the analysis and the future perspectives for improving 
the performance of the test, as well as its application in 
clinical practice. 
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Core tip: Multiple endocrine neoplasia type 1 (MEN1) is an 
autosomal dominant inherited tumour syndrome. Mutation 
analysis of the causative gene, the oncosuppressor 
MEN1  gene, is today the best approach for the early 
and differential diagnosis of the disease. The manuscript 
gives an overview on current genetic testing of MEN1 
syndrome, reporting the positive aspects and clinical 
utility of performing the analysis. Moreover, the paper 
aims to report the future perspectives for improving the 
performance of the test and its application in clinical 
practice. 
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INTRODUCTION
Multiple endocrine neoplasia type 1 (MEN1, OMIM 
131100) is a rare (approximately one in 30000) 
autosomal dominant inherited tumour syndrome 
with high penetrance (nearly 100% by the age of 
50), principally affecting parathyroid glands, entero-
pancreatic neuroendocrine tissues and anterior 
pituitary[1]. A variable combination of about 20 different 
endocrine and non-endocrine lesions and tumours 
can randomly occur in families and sporadic cases of 
the syndrome; despite the heritability of the disease, 
clinical features may differ in members of the same 
family and even between homozygote twins[2]. A MEN1 
case is clinically defined in a single patient showing 
at least two of the three main tumours or in a familial 
case presenting with one of the main syndrome-
related tumour and one first-degree relative affected 
by the syndrome. 
MEN1 syndrome occurs as the result of tumour 
growth and associated metastases which cause the 
overproduction of hormones. MEN1 patients have 
been shown to have a reduced life expectancy; 
approximately 30% to 40% of deaths are associated 
with malignant neuroendocrine pancreatic tumours 
(mainly gastrinomas) and thymic or bronchial carcinoid 
tumour (patients affected by these malignancies 
have a three-fold higher risk of death)[3]. The im-
proved management of MEN1-associated primary 
hyperparathyroidism and hypergastrinemia, as well as 
prophylactic ablation of thymus, have contributed to 
reduce the mortality of the syndrome. Paradoxically, 
the longer life expectancy could result in an increased 
risk for MEN1-associated malignancies. Indeed, current 
treatments, which are usually the same used for the 
sporadic tumour counterparts in non-MEN1 patients, 
are often not as successful in MEN1 patients because 
of the presence of multiple tumours in different organs, 
tumours that are generally more aggressive, larger and 
presenting with recurrences and metastases. An early 
diagnosis of the disease associated to pre-symptomatic 
tumour detection and specific therapy, starting as 
soon as possible, are, at the moment, the best and 
most effective way to grant MEN1 patients a better 
prognosis and a reduction of morbidity and mortality. 
The medical diagnosis of MEN 1 is commonly made by 
reconstruction of family history, physical examination 
of signs and symptoms of excess hormones, as well 
as specific biochemical screenings and imaging tests. 
These clinical and instrumental approaches usually 
allow a MEN1 diagnosis only during the fourth or fifth 
decades of life of the patient, delaying the performance 
of targeted surgical procedures and/or the initiation 
of available therapies. Biochemical detection of 
serum and/or urinary variations in hormones or other 
molecules deregulated by the presence of one or more 
MEN1-associated tumour can anticipate the disease 
diagnosis and tumour detection by about 5-8 years with 
respect to clinical onset and manifestation[4]. The early 
recognition of affected subjects and of at-risk individuals 
within a family can be further anticipated by DNA-
testing. Indeed, since the identification of the causative 
gene, the oncosuppressor gene MEN1 at the 11q13 
region, the genetic test, through MEN1 gene mutational 
analysis, has been revealed to be a fundamental 
approach for early and differential diagnosis of MEN1 
syndrome. The advantages of genetic testing are: 
it requires only a single blood sample, it can be 
performed at any age and, in theory, it does not need 
to be repeated during the patient’s lifetime. This paper 
provides a general overview on the current genetic 
approaches to MEN1 diagnosis, reporting the positive 
aspects and clinical utility of performing this analysis 
and explaining the future perspectives for improving 
the performance of the test and its application in clinical 
practice.
GENETIC TEST IN MEN1: GENETIC 
BASIS FOR CLINICAL MANAGEMENT OF 
PATIENTS
MEN1 syndrome is caused by inactivating mutations 
of the MEN1 gene, encoding for the nuclear protein 
menin. MEN1 exhibits an autosomal dominant pattern 
of inheritance, and each affected patient has a 50% 
probability of transmitting the genetic defect and 
disease predisposition to offspring, independent of 
sex. Also, all the first-degree relatives of a mutation 
carrier have a 50% risk of inheriting the mutation 
and developing the disease. The proposed model for 
tumorigenesis in MEN1 was according to Knudson’s 
“two hit” hypothesis for tumour suppressor genes[5]. A 
mutated allele of the MEN1 gene is inherited from the 
affected parent or developed at embryonic level (first 
hit); the second wild type allele is lost at somatic cell 
level (second hit). Tumours develop after inactivation 
of both MEN1 copies at chromosome 11q13, with 
acquisition of a homozygous recessive state at 
the tissue level. The absence of wild type menin is 
responsible for tumour development, but the exact 
molecular mechanisms of MEN1 tumorigenesis must 
still be completely clarified and are strongly suspected 
to be tissue-specific[6]. Moreover, the great clinical 
variability even between members of the same MEN1 
family and/or between patients bearing the same 
MEN1 mutation may lead to suspicion regarding the 
influence of other genetic (i.e., the contemporaneous 
presence of genetic variations and polymorphisms 
in genes other than MEN1) and non genetic tumour-
predisposing cofactors[7]. The presence of a MEN1 
mutation is associated with the development of the 
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syndrome with a nearly complete penetrance by the 
age of 50[8]. To date, no cases of mutation carriers 
who have not developed at least one of the MEN1-
associated tumours during their lifetime have been 
described. Recently, a novel mutation in exon 2 of the 
MEN1 gene (Leu143His) has been associated with a 
limited penetrance and a specific phenotype; family 
members bearing the mutation presented a mild or 
even absent primary hyperparathyroidism and multiple 
well-differentiated functionally active neuroendocrine 
tumours of the pancreas[9]. 
In general, the identification of a MEN1 mutation 
represents a positive genetic diagnosis of MEN1. 
Mutation analysis of the MEN1 gene allows an early 
identification of subjects who will develop MEN1 
syndrome and it is strongly recommended for: (1) 
index cases meeting the clinical criteria for MEN1 
syndrome (sporadic case affected by at least two of 
MEN1-related main tumours or individual with one of 
the MEN1-related main tumour and with a first-degree 
relative affected by at least one of MEN1-related 
main tumours); (2) index cases not fully meeting 
clinical criteria for MEN1 but with two or more MEN1-
related lesions and/or recurring tumours; and (3) 
asymptomatic first-degree relatives of a patient with 
an identified MEN1 mutation.
Before the discovery and positional cloning of 
the MEN1 gene in 1997, the genetic ascertainment 
of the syndrome consisted of haplotype analysis, 
using microsatellite markers at the 11q13 locus, in 
MEN1 affected kindred[10]. The analysis consists of a 
polymerase chain reaction (PCR)-based haplotype 
analysis of a series of microsatellite markers flanking, 
both at centromeric and telomeric sides, the 11q12-13 
region containing the MEN1 gene. Some of these 
markers exhibit recombination 0 with the MEN1 gene 
(i.e., PYGM, D11S463, D11S427) granting the test 
for carriers to reach up to 99.5% of accuracy and 
excluding incorrect results due to meiotic crossing over. 
The analysis requires the availability of a MEN1 family 
with at least two living clinically affected members, 
spanning at least two generations, and it allows for 
the identification, in affected individuals, of the family-
specific 11q13 risk haplotype. This screening presents 
the limitation that it cannot be applied to a single 
index case. With the reconstruction of haplotypes of 
all the members of the family it is possible to assess 
who inherited the predisposing 11q13 haplotype. Since 
the discovery of the MEN1 gene this kind of diagnostic 
approach has been replaced by the PCR-based 
sequencing analysis of the gene itself. However, the 
haplotype analysis is still useful and is suggested for 
the identification of gene carriers in MEN1 families in 
which a MEN1 gene mutation has not been identified. 
After the positional cloning of the MEN1 gene and 
its identification as the gene for MEN1 syndrome, the 
genetic diagnosis of MEN1 consists in the mutation 
analysis of the coding regions (exons 2-10) and intron-
exon junctions of this gene. The great majority of 
laboratories worldwide currently use selective PCR-
based amplifications of MEN1 exons and splicing 
sites, followed by specific PCR-based incorporation of 
dideoxynucleotides according to Sanger sequencing 
strategies. The MEN1 gene consists of 10 exons 
encoding for a main mRNA transcript of 2.8 Kb. Less 
commonly mRNA transcripts have been also described, 
presenting variations of the 5’-untranslated region but 
not of the coding region[11]. The entire exon 1 (in some 
cases referred as two distinct exons, as reported on 
the NCBI Gene database: Gene ID: 4221) and part 
of exons 2 and 10 are non coding regions, and, thus, 
exon 1 is conventionally non-included in the mutation 
screening. Mutations in the MEN1 promoter region 
have not been described[5]. About 70%-90% of MEN1 
families and sporadic cases result to be carriers of a 
MEN1 mutation; some studies reported that 5%-10% 
of patients do not have an identifiable mutation in the 
coding region or in splice sites of the gene[7]. They 
may have mutations in the promoter, introns or 
untranslated regions that normally are not analysed in 
genetic tests, or they may bear a gross gene deletion/
insertion that cannot be identified by the classical 
MEN1 sequencing analysis. Large gene deletions, 
insertions or other gross rearrangements can be 
detected by Southern blot analysis or by other gene 
dosage procedures. Multiplex ligation-dependent probe 
amplification (MLPA) is a quantitative highly sensitive 
and accurate multiplex PCR technique able to detect 
copy number changes within a gene and, thus, identify 
the presence of entire exons and/or whole gene loss or 
other gross intra-genic modifications. MLPA diagnostic 
screening should be considered in MEN1 index cases 
with a negative MEN1 sequencing test, to detect large 
MEN1 coding region deletions/duplications. In case of 
both sequencing and MPLA negative screenings, the 
application of familial haplotype analysis should be 
considered[12]. 
Patients with MEN1-like clinical phenotypes but 
negative to MEN1 genetic tests may also represent 
phenocopies. Phenocopies may mimic MEN1 either by 
occurrence of a single sporadic endocrine tumour within 
a MEN1 kindred or of two endocrine tumours/lesions 
associated with different aetiologies and, thus, they can 
confound clinical diagnosis of the disease. It is estimated 
that phenocopies may arise in up to 5% of MEN1 
families[13]; their recognition, also by specific genetic 
tests, is very important in the clinical management of 
MEN1 patients. In particular, the multiple neoplasia 
type 4 (MEN4) syndrome, a rare hereditary tumour 
syndrome presenting clinical manifestations overlapping 
with those of MEN1 but caused by inactivating mutations 
of the CDKN1B gene, should be strongly suspected, and 
the CDKN1B gene should be screened for mutations. 
Indeed, to date, nine different inactivating mutations 
of the CDNK1B gene (including missense, nonsense 
and frameshift variations and mutations in the 5’UTR 
of the gene) have been identified in 9 patients with a 
clinical MEN1-like syndrome but without any identified 
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mutation carriers. However, the individuation of any 
MEN1 mutation in an individual gives indications for 
a lifelong routine of clinical surveillance for MEN1-
associated tumours and lesions, indicates some surgery 
procedures and enables the specific mutation analysis 
for first-degree relatives in order to individuate mutation 
carriers. In the presence of a MEN1 mutation lifelong 
specific clinical surveillance is suggested, as specifically 
reported in Table 1. These guidelines are reported 
according to the most recent “clinical practice guidelines 
for Multiple Endocrine Neoplasia type 1” drafted 
by the leading worldwide specialists in this field[16]. 
Moreover, a positive test can also determine the type 
of surgical intervention for MEN1-associated primary 
hyperparathyroidism, leading to the decision for a total 
parathyroidectomy to prevent future recurrences of 
parathyroid adenomas, instead of the selective ablation 
of only the adenomatous gland/glands in subjects 
with a negative MEN1 genetic test. In MEN1 mutation 
carriers also a prophylactic thymectomy is also strongly 
suggested, at the same time as the parathyroid 
surgery, to prevent the occurrence of thymic carcinoids 
and related malignancies and to remove possible intra-
thymic ectopic/supra-numerary parathyroid glands. A 
positive test may also direct prenatal decisions, such 
as the performance of in vitro fertilization with pre-
implantation genetic selection of non-mutated embryos 
or MEN1 prenatal genetic test in a naturally occurring 
foetus. Conversely, a negative test in a MEN1 family 
member is an indication for no further biochemical 
and instrumental MEN1-related screenings and for no 
prenatal genetic testing. 
FUTURE PERSPECTIVES IN MEN1 GE-
NETIC TEST
As mentioned above, the great majority of laboratories 
worldwide performing the genetic test for MEN1 
syndrome, uses PCR-amplification of exons and splicing 
sites, followed by the PCR-based Sanger sequencing 
method. Only some of these laboratories also perform 
MPLA or linkage analyses in case of a negative 
sequencing result. These approaches fail to detect 
possible mutations in non coding and regulatory regions 
as well as identify phenocopies. The identification 
of possible phenocopies for the correct differential 
analysis of tumour endocrine syndromes would require 
a sequential traditional Sanger sequencing of all 
the associated genes, an extremely time-consuming 
approach. Next generation sequencing (NGS) is a novel 
sequencing technology that could allow these limitations 
to be bypassed, increasing the strength, efficacy, 
completeness and speed of genetic analysis. Application 
of NGS to the genetic diagnosis of the disease permits, 
at the same time, the sequencing of the coding regions, 
the introns, the untranslated and the regulatory regions, 
allowing the large intra-genic deletions/duplications 
to be recognised and the identification of novel 
MEN1 mutation[14]. However, because of the rarity of the 
MEN4 syndrome, the very small number of CDKN1B 
mutated patients, and the still unclear data about 
molecular mechanisms underlying MEN4 tumorigenesis, 
specific surveillance programs and specific clinical and 
therapeutic guidelines are not yet available for this 
syndrome, and the clinical management of patients 
overlaps that of MEN1 syndrome. Recently Longuini 
et al[15] found an association between the CDKN1B 
rs2066827 polymorphic variant and tumour multiplicity 
in patients bearing a MEN1 germline mutation. In 
MEN1 patients over 30 years of age with a MEN1 
truncating mutation, the presence of rs2066827 T allele 
was strongly higher in subjects with susceptibility to 
tumours in multiple glands (3 or 4 affected glands vs 1 
or 2 affected glands). These data need to be confirmed 
by additional studies and by functional analyses but 
they seem to suggest that the CDKN1B gene may act 
as a disease modifier in MEN1 syndrome in association 
to MEN1 mutation, influencing the severity of disease 
clinical outcomes. In addition, less than 2% of clinical 
MEN1 patients without MEN1 mutation may have 
mutations or polymorphisms in members of the cyclin-
dependent kinase inhibitor (CDKN) family, other than 
CDKN1B, such as CDKN1A, CDKN2B, or CDKN2C genes 
encoding, respectively, the p21cip1, p15Ink4b, p15Ink4c 
proteins, which all negatively regulate the cell cycle 
progression and cell growth[7]. Genetic analyses of these 
genes should be considered in patients with classical 
clinical manifestations of MEN1 but have resulted 
negative for MEN1 and CDKN1B mutations. 
Lemos and Thakker[7] in 2008 created a database 
of published MEN1 mutations by searching the NCBI 
PubMed scientific publication database for article in 
English. No uploaded mutation database has been 
published or released after that. They reported a total 
of 1133 different germline and 203 somatic mutations. 
Twenty-four polymorphisms (12 in the coding region, 
of which 10 synonymous and 2 non-synonymous, 
9 in the introns and 3 in the untranslated exonic 
regions) have also been described. MEN1 mutations 
are scattered along the entire 1830 bp coding region 
without showing any hot spot, making genetic analysis 
labour-intensive. Mutations are different in their types: 
20% missense mutations, 23% nonsense mutations, 
41% frameshift insertions or deletions, 6% in-frame 
insertions or deletions, 9% splice site mutations and 
1% large deletions. About 80% of all identified MEN1 
mutations are responsible for a truncated protein 
unable to reach the nucleus of the cells and exerting 
its role of oncosuppressor[1]. 
Unfortunately, no genotype-phenotype correlation 
has been reported, and the identification of a specific 
MEN1 mutation and/or a specific mutated region of 
menin does not allow the prediction of clinical outcomes 
of the disease, strongly reducing the importance 
of genetic information for the individual clinical 
management of both affected and asymptomatic 
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unexpected causative mutations. This method allows 
the enlargement of nucleotide sequencing from single-
gene to multi-gene-disease-targeted panels and up to 
the entire genome using platforms and instruments 
capable of producing hundreds of gigabytes of genetic 
data in a single run. The technique gives a less-
expensive and higher-throughput alternative to DNA 
sequencing compared to the traditional Sanger method. 
Moreover, NGS provides a high degree of flexibility for 
the level of resolution required for any single genetic 
analysis and a sequence run can be specifically tailored 
to produce more or less data and/or to screen one or 
more preselected regions of the genome or a specifically 
designed set of genes. Two alternative approaches 
for the detection of gene mutations are available: (1) 
the sequencing of the entire human genome, which 
facilitates the discovery of genes and regulatory 
elements, even unknown, associated with diseases; 
and (2) NGS targeted multi-gene sequencing, using a 
platform including a selected panel of genes (usually 
including all the coding, non coding and regulatory 
regions of each gene), which allows the identification 
of disease-causing mutations for the genetic diagnosis 
of a specific disease or a group of related disorders 
(i.e., hereditary endocrine tumours). The first approach 
is suggested for diseases with a suspected genetic 
origin but for which the causative gene/genes are not 
yet known. The second approach will be useful for the 
differential genetic diagnosis of hereditary endocrine 
tumours by the design of a specific platform including all 
the genes associated, up to date, to these pathologies. 
In 2013 Rattenberry et al[16] tested a targeted NGS 
platform, including 9 causative genes, for the genetic 
diagnosis of patients with pheochromocytoma and 
paraganglioma, allowing this NGS-based test to be 
established, validated and introduced into diagnostic 
practice. Very recently Welander et al[17] enlarged the 
targeted NGS platform for the mutation analysis of 
pheochromocytoma and paraganglioma, including 14 
different susceptibility genes, proving to be a cost- and 
time-reducing effective genetic diagnostic method for 
these tumours. A similar NGS-targeted approach was 
applied to the detection of mutations in thyroid cancer 
(ThyroSeq panel including 12 cancer genes with 284 
mutational hot spots)[18], and also in this case NGS 
was revealed to be an optimal genetic test for multiple 
genes with high accuracy and very good sensitivity. 
These promising results suggest possible development 
and application of an NGS targeted platform for the 
mutation analysis of multiple endocrine neoplasia 
syndromes and inherited endocrine tumours in the near 
future. The classical Sanger monogenic sequencing 
method should be maintained as a pre-screening test 
in all the suspected MEN1 probands and also for the 
research of a specific mutation in relatives of MEN1 
mutated individuals, while targeted NGS analysis 
should be applied routinely to patients showing clinical 
manifestations of MEN1 but resulting to be negative 
from classical Sanger sequencing of the MEN1 and the 
CDKN1B genes. 
CONCLUSION
The possibility of genetic testing has facilitated 
increased praecox and specific diagnosis of MEN1 
syndrome. Even if it is a rare disease, and despite the 
fact that the presence of a specific MEN1 mutation 
does not allow the prediction of clinical phenotype, the 
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Table 1  Suggested guidelines for biochemical and instrumental surveillance screenings in individuals bearing any MEN1  gene 
mutation
Tumour/lesion Recommended age of 
begin screenings (yr)





8 Fasting total serum calcium concentration 
(corrected for albumin) and/or ionized-
serum calcium concentration
Yearly None NA
Fasting serum concentration of full-length 
PTH
Gastrinoma 20 Fasting serum gastrin concentration Yearly None NA






Under 10 Serum concentration of chromogranin-A, 
glucagone, pancreatic polypeptide, 
vasoactive intestinal peptide





5 Serum concentration of prolactin and 
insulin-like growth factor-1 
Yearly Head MRI Every 3-5 yr (depending 




Under 10 None unless symptoms or signs of 
functioning tumour and/or tumour > 1 cm 
are recognised by imaging
NA Abdominal CT 
or MRI
Yearly with pancreatic imaging
Thymic and 
bronchial carcinoid
15 None NA Thoracic CT or 
MRI
Every 1-2 yr
CT: Computed tomography; MRI: Magnetic resonance imaging; EUS: Endoscopic ultrasound; NA: Not applicable.
Marini F et al . MEN1 genetic diagnosis
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finding of a MEN1 mutation in a patient has important 
implications for his/her clinical surveillance and for 
clinical management of first-degree relatives. The 
application of genetic diagnosis, and the subsequent 
early identification of at-risk individuals have contributed, 
in the last two decades, to the reduction of morbidity 
and mortality of patients. 
A genetic positive test, predicting the future 
development of MEN1, may ultimately have an important 
psychological impact on the proband and his/her 
family, often causing distress, anxiety, depression, etc. 
Clinical practice guidelines for MEN1[16] recommend 
that MEN1 patients and their families be followed by a 
multidisciplinary team of specialists, with experience 
in the diagnosis and treatment of endocrine tumours, 
including genetic counselling before and after the 
genetic tests are carried out. The genetic counselling, 
performed by a professional from the discipline of 
medicine or genetics, should include the correct and 
detailed explanation of psychosocial benefits and risks 
of the genetic test result, as well as its influence in 
clinical management and quality of life of the patient 
and his/her relatives. In general, collaboration between 
genetic counsellors, laboratories and clinicians could help 
a patient (and his/her family) to understand the clinical 
meaning of his/her genetic test result, whether positive, 
negative, or indeterminate, and better plan preventive 
screenings and therapeutic approaches.
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